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 criteria exist for a given disorder, then surely 
it is unethical to categorically exclude chil-
dren and adolescent patients from receiv-
ing the only treatment available that could 
dramatically increase their quality of life. 
Experts that oppose the use of DBS for 
pediatric TS (Mink et al., 2006; Porta et al., 
2009) defend their position based upon 
the nature of childhood TS. According to a 
recent review, by early adulthood, approxi-
mately three quarters of children with TS 
will have greatly diminished tics and more 
than one-third will be tic free (Bloch and 
Leckman, 2009). A recent follow-up study 
on childhood and adolescent OCD found 
that 60% of children and adolescents did 
not have a full clinical disorder at follow-
up, and two-thirds of participants rated 
themselves as much improved (Micali 
et al., 2010). According to the authors, many 
young people adapt to their illness and can 
lead a fairly normal life despite their symp-
toms. These are indeed important findings 
that highlight the exceptional caution that 
is needed when considering pediatric DBS 
for disorders that may spontaneously dis-
appear or become subclinical over time. 
However, do they warrant the categorical 
exclusion of child patients? As Mink et al. 
(2006) themselves put forward: “Remission 
of tics may occur in the third decade of 
life in up to 50% of patients, but to date, 
there are no prognostic features that pre-
dict which patients will have a remission 
in their symptoms”(p.1832), and according 
to experts, the situation remains the same 
today. Which means that we do not pos-
sess clear scientific criteria to warrant the 
categorical exclusion of all child patients.
Children with severe treatment- 
refractory diseases are an extremely vul-
nerable group, and they should not be 
exposed to an invasive intervention like 
DBS unless successful treatment outcomes 
have been established in adults. However, if 
treatment success for neurological or psy-
chiatric disorders is established in adults, 
and provided no clear scientific criteria 
exist to categorically exclude minors, then 
children and adolescents can be involved 
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Today, deep brain stimulation (DBS) is 
performed to treat dystonia in children as 
young as 7 years of age (Roubertie et al., 
2000). For a variety of reasons, timely inter-
vention in childhood dystonia is important: 
(1) to prevent irreversible damage, (2) to 
obtain optimal treatment outcomes, since 
severity and duration of the disease are 
negative prognostic factors for successful 
DBS treatment, and (3) to prevent long-
term social costs due to social isolation 
(Isaias et al., 2008; Mehrkens et al., 2009; 
Clausen, 2010). Individual cases of DBS for 
neuropsychiatric disorders in adolescents 
have been published over the last 3 years 
(e.g., Shaded et al., 2007). Considering 
the investigational nature of DBS for psy-
chiatric disorders, this is unsettling to say 
the least.
A group of experts recently proposed 
guidelines for the use of DBS for disorders 
of mood, behavior and thought (Rabins 
et al., 2009). Due to the investigational 
nature of DBS for psychiatric disorders, they 
defend the position that, at present, DBS 
for mood, behavior and thought disorders 
should be reserved for adults. However, they 
also put forward that “if DBS is found to be 
safe and effective for adults, then it might be 
appropriate to investigate its benefits for a 
younger population with severe, treatment-
refractory symptoms” (p. 933). Their opin-
ion is quite different from the statement 
made by another group of experts on the 
use of DBS for Tourette syndrome (TS) in 
children (Mink et al., 2006). They argue that 
patients should be at least 25 years old, with 
rare potential exceptions involving younger 
patients. Bloch and Leckman (2009) simi-
larly claim that “invasive interventions 
for TS such as DBS and neurosurgery are 
strongly discouraged until well into adult-
hood, even for patients with impairing tics” 
(p. 499).
Is it ethical to categorically exclude chil-
dren and adolescent patients from receiv-
ing DBS for treatment-refractory disorders 
such as TS? If clear scientific criteria exist 
why specific pediatric disorders need to 
be excluded, then yes. However, if no such 
in  small-scale, early-phase studies  provided 
these are done in research centers. Children 
with treatment-refractory disorders should 
not be categorically excluded from receiving 
DBS treatment, and this holds for any dis-
order for which treatment success has been 
established in adults and for which no clear 
scientific criteria exist that warrant their 
exclusion. Moreover, it is crucial that the 
decision-making process is a shared proc-
ess between the child patient, the medical 
experts and the parents or parental guard-
ians to maximally protect the vulnerable 
child patient. The decision-making proc-
ess should involve a dual consent procedure 
with parents giving informed consent and 
children giving explicit assent. Medical 
experts should not start treatment in those 
cases where the only benefit to incur would 
be relief of caregiver burden. Unless clear 
scientific data can show that a child patient 
would benefit by receiving DBS treatment 
and would be harmed if not given treatment 
(e.g., cases of severe childhood dystonia), 
DBS treatment should not be performed 
if the child patient dissents. If successful, 
timely DBS treatment for dystonia ben-
efits both the child patient (by preventing 
irreversible harm and long-term social 
costs due to social isolation, and provid-
ing optimal treatment outcomes) and the 
caregiver. Hence, we have strong reasons to 
consider DBS treatment in a timely fashion, 
and potentially even in those cases where 
the child patient dissents. This is not so for 
certain other disorders. If DBS treatment 
is performed for childhood TS or OCD 
that might have spontaneously remitted 
or become subclinical with time, then the 
dissenting child patient is harmed because 
an unnecessary invasive procedure was 
forced upon him/her, and the only ben-
efit that occurred is a third-party benefit 
(i.e., caregiver relief). In fact, treatment 
compliance is a patient selection require-
ment according to the Italian DBS group 
treating TS (Porta et al., 2009). Indeed, it is 
crucial that the decision-making procedure 
is a shared process between child patients, 
medical experts and parents: (a) to ensure 
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